Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Empagliflozin for proteinuria in type 2 diabetes
IRCT20190425043368N2Phase 3Completed
- Sponsor
- Shahid Sadoughi University of Medical Sciences
- Start
- Oct 2025
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, single-blind trial in type 2 diabetes mellitus (T2DM) comparing Empagliflozin with Placebo (2 arms). Primary endpoint: Urinary protein excretion. Started Oct 2025; status: completed.
02
Drugs
empagliflozin
03
Conditions
type 2 diabetes mellitus (T2DM)
Beyond the preview
Go deeper on IRCT20190425043368N2.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on IRCT20190425043368N2.